Drug Profile
Research programme: nanotechnology-based therapeutics - Cerulean Pharma
Alternative Names: cabazitaxel NDCs; cabazitaxel β-cyclodextrin-PEG copolymer-based nano-particle-drug conjugate; CRLX 288Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cerulean Pharma
- Class Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Controlled release)